Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)

被引：0

作者：

Hideki Kato

Masaomi Nangaku

Hideki Hirakata

Takashi Wada

Terumasa Hayashi

Hiroshi Sato

Yasushi Yamazaki

Takao Masaki

Tatsuo Kagimura

Hiroyasu Yamamoto

Hiroki Hase

Masahiro Kamouchi

Enyu Imai

Kyoichi Mizuno

Manabu Iwasaki

Tadao Akizawa

Yoshiharu Tsubakihara

Shoichi Maruyama

Ichiei Narita

机构：

[1] The University of Tokyo Graduate School of Medicine,Division of Nephrology and Endocrinology

[2] Fukuoka Renal Clinic,Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences

[3] Kanazawa University,Department of Kidney Disease and Hypertension

[4] Osaka General Medical Centre,Division of Clinical Pharmacology and Therapeutics

[5] Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences,Department of Nephrology and Rheumatology

[6] Kagawa Prefectural Central Hospital,Department of Nephrology

[7] Hiroshima University Hospital,Department of Internal Medicine

[8] Translational Research Informatics Center,Division of Nephrology

[9] Foundation Biomedical Research and Innovation,Department of Health Care Administration and Management, Graduate School of Medical Sciences

[10] Atsugi City Hospital,Nakayamadera Imai Clinic, Takarazuka, Hyogo, Department of Nephrology

[11] Toho University Ohashi Medical Center,Department of Computer and Information Science

[12] Kyushu University,Division of Nephrology, Department of Medicine

[13] Fujita Health University Toyoake,Course of Safety Management in Health Care Sciences, Graduate School of Health Care Sciences

[14] Mitsukoshi Health and Welfare Foundation,Department of Nephrology

[15] Seikei University,Division of Clinical Nephrology and Rheumatology

[16] Showa University School of Medicine,undefined

[17] Jikei Institute,undefined

[18] Nagoya University Graduate School of Medicine,undefined

[19] Niigata University Graduate School of Medical and Dental Sciences,undefined

来源：

Clinical and Experimental Nephrology | 2018年 / 22卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：85 / 86

页数：1

共 50 条

[11] Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
Amnuay, Kamalas
Srisawat, Nattachai
Wudhikarn, Kitsada
Assanasen, Thamathorn
Polprasert, Chantana
HEMATOLOGY REPORTS, 2019, 11 (03) : 61 - 64
[12] Continuous erythropoiesis receptor activator (CERA) - An erythropoiesis-stimulating agent for the treatment of anemia in patients with chronic kidney disease
O'Mara, Neeta Bahal
Kapoian, Toros
FORMULARY, 2007, 42 (04) : 233 - +
[13] Effects of Anemia Correction by Erythropoiesis-Stimulating Agents on Cardiovascular Function in Non-Dialysis Patients With Chronic Kidney Disease
Suzuki, Makoto
Hada, Yoshiyuki
Akaishi, Makoto
Hiroe, Michiaki
Aonuma, Kazutaka
Tsubakihara, Yoshiharu
Akizawa, Tadao
INTERNATIONAL HEART JOURNAL, 2012, 53 (04) : 238 - 243
[14] OPTIMAL TARGET HEMOGLOBIN LEVEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND ANEMIA TREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS: CONTROVERSIAL ISSUES
Kozlovskaya, L. V.
Milovanov, Yu. S.
Milovanova, L. Yu
ARCHIV EUROMEDICA, 2011, 3 : 55 - 64
[15] Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: Overcoming the pharmacological and pharmacoeconomic limitations of existing therapies
Wish, Jay B.
Coyne, Daniel W.
MAYO CLINIC PROCEEDINGS, 2007, 82 (11) : 1371 - 1380
[16] Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
Saglimbene, Valeria
Palmer, Suetonia C.
Craig, Jonathan C.
Ruospo, Marinella
Nicolucci, Antonio
Tonelli, Marcello
Johnson, David
Lucisano, Giuseppe
Williams, Gabrielle
Valentini, Miriam
D'Alonzo, Daniela
Pellegrini, Fabio
Strippoli, Paolo
Salomone, Mario
Santoro, Antonio
Maffei, Stefano
Hegbrant, Joergen
Tognoni, Gianni
Strippoli, Giovanni F. M.
PLOS ONE, 2017, 12 (03):
[17] ECONOMIC BURDEN OF ADVERSE EVENTS ASSOCIATED WITH ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF ANEMIA AMONG CHRONIC KIDNEY DISEASE PATIENTS IN TAIWAN
Guan, S. T.
Chen, H. M.
Hsiao, F. Y. S.
VALUE IN HEALTH, 2022, 25 (07) : S440 - S440
[18] Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis
Molina, Manuel
Jose Navarro, Maria
de Gracia, Carmen
Alvarez, Gracia
de Alarcon, Rosa
Angeles Garcia, Maria
RENAL FAILURE, 2008, 30 (08) : 778 - 783
[19] Monthly darbepoetin-alfa administration in treating anemia in renal transplant recipients: Comparison with chronic kidney disease patients.
Attallah, Nizar
Frinak, Stan
Karthikeyan, Vanji
Faber, Mark
Yee, Jerry
Ramanathan, Sundar
Venkat, K. K.
Parasuraman, Ravi
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 360 - 360
[20] Dosing intervals and hemoglobin control in patients with anemia of chronic kidney disease treated with erythropoiesis stimulating agents
Nurko, Saul
Spirko, Rita
Law, Amy
Dennis, Vincent W.
AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (04) : A63 - A63

← 1 2 3 4 5 →